Fox Run Management L.L.C. Makes New $667,000 Investment in Repligen Co. (NASDAQ:RGEN)

Fox Run Management L.L.C. acquired a new stake in shares of Repligen Co. (NASDAQ:RGEN) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 4,635 shares of the biotechnology company’s stock, valued at approximately $667,000.

Several other hedge funds have also recently made changes to their positions in RGEN. Raymond James Financial Inc. purchased a new stake in Repligen during the 4th quarter valued at about $52,492,000. Allspring Global Investments Holdings LLC boosted its position in Repligen by 79.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company’s stock valued at $65,395,000 after buying an additional 203,011 shares during the last quarter. DF Dent & Co. Inc. increased its holdings in Repligen by 31.0% in the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock worth $87,852,000 after buying an additional 139,615 shares during the period. Two Sigma Advisers LP raised its position in Repligen by 421.9% during the 3rd quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company’s stock worth $18,796,000 after buying an additional 102,100 shares during the last quarter. Finally, Fred Alger Management LLC lifted its stake in Repligen by 29.5% during the 3rd quarter. Fred Alger Management LLC now owns 398,554 shares of the biotechnology company’s stock valued at $59,313,000 after acquiring an additional 90,831 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Stock Up 3.7 %

Shares of NASDAQ RGEN opened at $145.15 on Tuesday. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $198.00. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company’s 50-day simple moving average is $155.91 and its 200-day simple moving average is $148.40. The firm has a market cap of $8.15 billion, a price-to-earnings ratio of -284.61, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Equities analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

RGEN has been the subject of several recent research reports. TD Cowen assumed coverage on shares of Repligen in a report on Monday, February 10th. They set a “buy” rating and a $200.00 target price for the company. Royal Bank of Canada boosted their price objective on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. Canaccord Genuity Group raised their target price on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a report on Friday, February 21st. HC Wainwright reissued a “buy” rating and issued a $180.00 price target on shares of Repligen in a report on Friday, February 21st. Finally, JPMorgan Chase & Co. raised their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $178.64.

Insider Activity at Repligen

In other Repligen news, Director Margaret Pax acquired 250 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.20% of the stock is owned by corporate insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.